mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection

International Journal of Molecular Sciences

Rose Li¹  Lu Zhang²  Shuqin Xu²  Kunpeng Yang² 

[1] M.B.B.S., School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China;State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai 200438, China;

关键词: mRNA;    mRNA vaccine;    in vitro transcription;    self-adjuvanting property;    delivery carriers;    infectious diseases;   

DOI  :  10.3390/ijms21186582

来源: DOAJ

【 摘 要 】

Messenger ribonucleic acid (mRNA)-based drugs, notably mRNA vaccines, have been widely proven as a promising treatment strategy in immune therapeutics. The extraordinary advantages associated with mRNA vaccines, including their high efficacy, a relatively low severity of side effects, and low attainment costs, have enabled them to become prevalent in pre-clinical and clinical trials against various infectious diseases and cancers. Recent technological advancements have alleviated some issues that hinder mRNA vaccine development, such as low efficiency that exist in both gene translation and in vivo deliveries. mRNA immunogenicity can also be greatly adjusted as a result of upgraded technologies. In this review, we have summarized details regarding the optimization of mRNA vaccines, and the underlying biological mechanisms of this form of vaccines. Applications of mRNA vaccines in some infectious diseases and cancers are introduced. It also includes our prospections for mRNA vaccine applications in diseases caused by bacterial pathogens, such as tuberculosis. At the same time, some suggestions for future mRNA vaccine development about storage methods, safety concerns, and personalized vaccine synthesis can be found in the context.

【 授权许可】

Unknown